Subscribe
24 June 2025NewsAmericasSarah Speight

A step too far? Why Stewart’s approach is dividing opinion

Coke Morgan Stewart has issued a raft of decisions under new guidance intended to improve the US patent appeals board process. But it’s a divisive issue, finds Sarah Speight.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Vidal: Coke Morgan Stewart's rulings are 'taxing innovation'
12 June 2025   Two decisions by acting USPTO director Coke Morgan Stewart have “damaging” consequences, warns Vidal | Stewart kickstarts campaign of implied criticism of predecessor’s record.
Americas
USPTO’s Stewart: Don’t nix patents as penalty for misconduct
10 June 2025   Office’s acting director lifts severe penalties against patent owner following Federal Circuit remand | Issues separate decision highlighting consequences of “lengthy awareness” of patent portfolio.
Big Pharma
‘Choose your IP armour carefully’: Novartis, HP, Nestlé and Vidal
5 June 2025   Companies face increasingly complex decisions over what IP to use, particularly when collaborating. Muireann Bolger hears the dos and don’ts of protection from senior counsel.


Editor's picks

Diverging in the detail: UPC local divisions and Court of Appeal take different paths
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025

Editor's picks

Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025

More on this story

Americas
Vidal: Coke Morgan Stewart's rulings are 'taxing innovation'
12 June 2025   Two decisions by acting USPTO director Coke Morgan Stewart have “damaging” consequences, warns Vidal | Stewart kickstarts campaign of implied criticism of predecessor’s record.
Americas
USPTO’s Stewart: Don’t nix patents as penalty for misconduct
10 June 2025   Office’s acting director lifts severe penalties against patent owner following Federal Circuit remand | Issues separate decision highlighting consequences of “lengthy awareness” of patent portfolio.
Big Pharma
‘Choose your IP armour carefully’: Novartis, HP, Nestlé and Vidal
5 June 2025   Companies face increasingly complex decisions over what IP to use, particularly when collaborating. Muireann Bolger hears the dos and don’ts of protection from senior counsel.

More on this story

Americas
Vidal: Coke Morgan Stewart's rulings are 'taxing innovation'
12 June 2025   Two decisions by acting USPTO director Coke Morgan Stewart have “damaging” consequences, warns Vidal | Stewart kickstarts campaign of implied criticism of predecessor’s record.
Americas
USPTO’s Stewart: Don’t nix patents as penalty for misconduct
10 June 2025   Office’s acting director lifts severe penalties against patent owner following Federal Circuit remand | Issues separate decision highlighting consequences of “lengthy awareness” of patent portfolio.
Big Pharma
‘Choose your IP armour carefully’: Novartis, HP, Nestlé and Vidal
5 June 2025   Companies face increasingly complex decisions over what IP to use, particularly when collaborating. Muireann Bolger hears the dos and don’ts of protection from senior counsel.

More features

Boies Schiller Flexner adds three-strong litigation team
AstraZeneca forced to clarify deal terms in row with university
Novartis loses cancer drug patent following Teva challenge at EPO
WATCH: Section 112—Where has the dust settled?
UPC rejects Alexion’s rehearing bid in spat with Amgen and Samsung
Biotech seeks to stop Kirkland from representing rival in Eylea dispute
Regeneron hits Amgen over its blockbuster eye disease treatment
Diverging in the detail: UPC local divisions and Court of Appeal take different paths